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Abstract
To investigate the impact of sampling methodology on gene expression data from primary estrogen receptor–positive (ERþ)
breast cancer biopsies, global gene expression was measured in core-cut biopsies at baseline and surgery from patients
randomly assigned to receive either two weeks of presurgical aromatase inhibitor (AI; n ¼ 157) or no presurgical treatment
(n ¼ 56). Those genes most markedly altered in the AI group (eg, FOS, DUSP1, RGS1, FOSB) were similarly altered in the no
treatment group; some widely investigated genes that were apparently unaffected in the AI group (eg, MYC) were counter-
altered in the control group, masking actual AI-dependent changes. In the absence of a control group, these artefactual
changes would likely lead to the most affected genes being the erroneous focus of research. The findings are likely relevant to
all archival collections of ERþ breast cancer.
Analysis of gene expression in biopsies taken before and after
treatment of primary breast cancer (BC) is frequently undertaken
to study mechanisms of response and resistance. We and others
have identified artefactual changes in gene expression that can
result from the study procedures (1,2). Importantly, however, the
degree of impact of those changes has not been evaluated in the
context of a specific therapy. The current study reveals the po-
tential for profound errors in data interpretation that could occur
if such artefacts are not identified or are ignored.
The PeriOperative Endocrine Therapy-Individualising Care
(POETIC; CRUK/07/015) (3) trial randomly assigned 4486 post-
menopausal women with primary estrogen receptor–positive
(ERþ) BC 2:1 to receive perioperative aromatase inhibitor (AI;
two weeks presurgery þ two weeks postsurgery, termed AI-
treated) or no perioperative treatment (termed control).
Core-cut biopsy samples in RNA later were analyzed from both
the baseline and surgical sample from 213 patients (157 were
all good-quality available AI-treated and 56 were randomly cho-
sen controls). High-quality genome-wide expression data
(GSE105777) were analyzed to identify statistically significant al-
tered gene expression and were compared between the AI-
treated and control groups. Classical clinical factors were well
balanced between the two groups (Supplementary Table 1).
A total of 3269 genes (n ¼ 1504 upregulated, n ¼ 1765 down-
regulated) from treated tumors and 110 genes (n ¼ 70 upregu-
lated, n ¼ 40 downregulated) from control tumors were
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differentially expressed between baseline and surgical samples,
with P values of less than .001 by paired t test on the normalized
expression data (Supplementary Tables 2 and 3 and
Supplementary Figure 1, available online). In the control group,
25 of the top 30 differentially expressed genes ranked by an ab-
solute fold-change (FC) were upregulated at surgery (Table 1), as
previously reported (1). Many of these were early-response or
stress-associated genes (FOS, RGS1, DUSP1, FOSB, JUN, and MYC),
as well as CD69 (FC ¼ 1.39, P ¼ 1.48E-4), an early T-cell activation
antigen associated with immune response (4), and TOB1 (FC ¼
1.28, P ¼ 5.2E-06), an important mediator involved in T-cell acti-
vation and a critical determinant of estrogen-independent ERþ
BC survival (5). The five downregulated genes included those
encoding hemoglobin (HBA and HBB).
In the AI-treated cohort, in contrast to the mainly upregu-
lated genes in the control group, 22 of the top 30 ranked genes
(Table 1) were downregulated after two weeks of AI treatment.
Most of these corresponded to proliferation, estrogen-respon-
sive, or cycling genes. However, 11 of the 30 top-ranked differen-
tially expressed genes in the AI-treated group (eight upregulated
and three downregulated) were among the 12 most altered genes
in the control group, including FOS, DUSP1, and RGS1. These
latter three genes were the most affected in both cohorts. A scat-
terplot of the changes in individual gene expression between the
POETIC AI-treated and control cohorts (Figure 1) shows the near
identical quantitative levels of change for the genes most af-
fected by each treatment. In essence, the changes of greatest
magnitude in the AI-treated tumors are completely artefactual.
In addition, there are widely investigated genes, such as MYC,
that are statistically significantly altered in the control samples,
but apparently unaffected in the treated group. Correction for
the degree of change in MYC expression within the control group
reveals the highly statistically significant suppression of MYC as
a result of AI therapy (P ¼ .0003).
We examined gene expression data from an independent set
of core cuts taken at baseline and two weeks after starting AI
treatment in the FAIMoS study (6). The same markedly affected
genes identified in the POETIC AI-treated arm were not ob-
served in the top-ranked 30 genes identified in FAIMoS
(Supplementary Table 4). This discrepancy is likely to be
explained by the way the tissue core was taken and manipu-
lated after therapy. The key difference between the POETIC and
FAIMoS studies was that for the former the post-therapy core
was from an excised tumor while in FAIMoS the core was taken
from the breast with the tumor in situ. Thus, in FAIMoS, the
processes of sampling for the baseline and on-treatment core
biopsies were identical, while in POETIC, the second core biopsy
was subject to a variable degree of ischemic conditions prior to
Table 1. Top ranked genes in control and AI-treated samples. Top 30 regulated genes in control tumors and in AI-treated tumors.
Symbol
Rank in
control† FC (S/B) ‡
Parametric
p-value FDRˆ
Rank in
AI-treated† Symbol
Rank in
AI-treated† FC (S/B) ‡
Parametric
p-value FDR
Rank in
control†
FOS* 1 3.87 < 1x10-07 < 1x10-07 1 FOS* 1 4.14 < 1x10-07 < 1x10-07 1
RGS1* 2 3.22 < 1x10-07 < 1x10-07 3 DUSP1* 2 3.36 < 1x10-07 < 1x10-07 3
DUSP1* 3 3.06 < 1x10-07 < 1x10-07 2 RGS1* 3 3.33 < 1x10-07 < 1x10-07 2
HBA2* 4 -2.94 9.00x10-07 9.10x10-04 7 TFF1 4 -2.94 < 1x10-07 < 1x10-07 NA
HBB* 5 -2.86 3.40x10-06 2.06x10-03 7 FOSB* 5 2.65 < 1x10-07 < 1x10-07 7
HBA1* 6 -2.50 6.30x10-06 3.21x10-03 12 TOP2A 6 -2.56 < 1x10-07 < 1x10-07 NA
FOSB* 7 2.30 9.00x10-07 9.10x10-04 5 UBE2C 7 -2.44 < 1x10-07 < 1x10-07 NA
RNY5 8 -2.13 5.04x10-05 1.39x10-02 83 HBB* 7 -2.44 < 1x10-07 < 1x10-07 5
CYR61* 9 2.05 1.70x10-06 1.43x10-03 10 HBA2* 7 -2.44 < 1x10-07 < 1x10-07 4
EGR1* 10 1.98 1.00x10-06 9.47x10-04 10 EGR1* 10 2.36 < 1x10-07 < 1x10-07 10
ZFP36* 11 1.97 < 1x10-07 < 1x10-07 18 CYR61* 10 2.36 < 1x10-07 < 1x10-07 9
SNORD3D* 12 1.86 4.00x10-07 4.66x10-04 30 CDC20 12 -2.13 < 1x10-07 < 1x10-07 NA
TRK1 13 -1.72 < 1x10-07 < 1x10-07 49 NUSAP1 12 -2.13 < 1x10-07 < 1x10-07 NA
JUN 14 1.67 < 1x10-07 < 1x10-07 65 HBA1* 12 -2.13 < 1x10-07 < 1x10-07 6
SGK1 15 1.62 < 1x10-07 1.68x10-04 32 SUSD3 15 -2.04 < 1x10-07 < 1x10-07 NA
SNORD3A 15 1.62 1.61x10-05 6.10x10-03 79 FGFR3 16 -2.00 < 1x10-07 < 1x10-07 NA
SNORD3C 17 1.61 1.30x10-05 5.05x10-03 97 NEK2 17 -1.96 < 1x10-07 < 1x10-07 NA
LOC100132564 19 1.53 4.12x10-04 7.70x10-02 NA ZFP36* 18 1.94 < 1x10-07 < 1x10-07 11
RASD1 20 1.52 1.22x10-05 4.87x10-03 39 UHRF1 19 -1.92 < 1x10-07 < 1x10-07 NA
RGS2 21 1.51 9.74x10-05 2.38x10-02 33 PRC1 19 -1.92 < 1x10-07 < 1x10-07 NA
SNORD13 22 1.49 5.52x10-05 1.49x10-02 80 ASPM 19 -1.92 < 1x10-07 < 1x10-07 NA
CCL3L3 23 1.48 6.80x10-06 3.21x10-03 80 AGR2 19 -1.92 < 1x10-07 < 1x10-07 NA
KLF6 24 1.47 5.29x10-04 9.02x10-02 99 PDZK1 23 -1.85 < 1x10-07 < 1x10-07 NA
APOLD1 25 1.45 2.00x10-06 1.60x10-03 71 PTTG1 24 -1.82 < 1x10-07 < 1x10-07 NA
ATF3 26 1.43 3.71x10-05 1.12x10-02 138 ADCY1 24 -1.82 < 1x10-07 < 1x10-07 NA
SPRY1 26 1.43 9.59x10-05 2.38x10-02 36 CDCA5 26 -1.79 < 1x10-07 < 1x10-07 NA
MYC 28 1.41 2.28x10-05 8.23x10-03 NA CCNB2 26 -1.79 < 1x10-07 < 1x10-07 NA
CEBPD 29 1.39 4.60x10-06 2.68x10-03 226 KIAA0101 26 -1.79 < 1x10-07 < 1x10-07 NA
BTG2 29 1.39 9.20x10-06 3.77x10-03 138 STC2 26 -1.79 < 1x10-07 < 1x10-07 NA
CD69 29 1.39 1.48x10-04 3.31x10-02 65 SNORD3D* 30 1.77 < 1x10-07 < 1x10-07 12
*Highlights the 11 genes regulated in AI-treated group that are among the 12 most regulated genes in control. AI ¼ aromatase inhibitor; B ¼ baseline; FC ¼ fold-change;
FDR ¼ false discovery rate; S ¼ surgery.
†Rank: by an absolute fold-change.
‡FC (S/B): fold-change of individual genes at surgery compared with baseline.
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placement in RNA later. In many cases, the time of ischemia
will have been variably extended by the time taken to x-ray the
biopsy sample. Our earlier report described the changes that re-
sult from that delay in genes such as RGS1 and DUSP1, which
are among the most affected genes in the AI-treated and control
arms in POETIC. Of note, in support of this explanation, the de-
crease seen in MYC expression in the POETIC AI-treated group
after correction for the artefactual increase in the controls con-
curs with the statistically signifcant decrease seen in FAIMoS.
We conclude that the majority of the most upregulated
genes (eg, FOS, DUSP1, RGS1, FOSB) and a small number of the
most downregulated genes are identified as a result of pre-
analytical sample processing. In addition, the true effect of AI
treatment on other genes can be hidden by counteractive arte-
factual change. In the absence of a control group, investigators
are likely to focus on the most extensive gene changes, yet
these will include many ascribed wrongly to the effect of experi-
mental intervention; some genes that would be the focus will be
wrongly ignored because they are apparently unaffected by
therapy. It is notable that our observations have been made in
the context of withdrawal of estrogen stimulation, the strongest
transcriptional drive for ERþ BC. The artefacts are likely to be
pronounced relative to true effects in the context of less impact-
ful therapy. Future presurgical studies should ensure that core
cuts taken at surgery are either taken in an identical fashion to
those at baseline or that a control group of patients is included
to identify any process-related changes.
It should also be recognized that the majority of tissue-
related studies in BC occur in archival excision specimens that
will have been subject to similar or perhaps greater ischemic
conditions before fixation than the core-cut samples in POETIC.
Investigators should establish that the collection process does
not affect expression of the genes of interest prior to assuming
that the observed expression reflects the true expression in the
tumor in situ.
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